Key Highlights: Implications: This partnership accelerates peptide therapy access in high-growth markets, challenging incumbents like Sun Pharma in India’s $500M+ peptide segment whi...
Key Highlights: Implications: Kashiv’s scaling challenges Biocon/Serum Institute dominance in India’s $15B+ biologics CDMO space (18% CAGR), capturing 10-15% complex...
